JP2024522075A5 - - Google Patents
Info
- Publication number
- JP2024522075A5 JP2024522075A5 JP2023571801A JP2023571801A JP2024522075A5 JP 2024522075 A5 JP2024522075 A5 JP 2024522075A5 JP 2023571801 A JP2023571801 A JP 2023571801A JP 2023571801 A JP2023571801 A JP 2023571801A JP 2024522075 A5 JP2024522075 A5 JP 2024522075A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- binding fragment
- specifically binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021095113 | 2021-05-21 | ||
| CNPCT/CN2021/095113 | 2021-05-21 | ||
| CN2022085625 | 2022-04-07 | ||
| CNPCT/CN2022/085625 | 2022-04-07 | ||
| CN2022088172 | 2022-04-21 | ||
| CNPCT/CN2022/088172 | 2022-04-21 | ||
| PCT/CN2022/093565 WO2022242680A1 (en) | 2021-05-21 | 2022-05-18 | Anti-cea and anti-cd137 multispecific antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024522075A JP2024522075A (ja) | 2024-06-11 |
| JP2024522075A5 true JP2024522075A5 (cg-RX-API-DMAC10.html) | 2025-05-22 |
Family
ID=84140249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571801A Pending JP2024522075A (ja) | 2021-05-21 | 2022-05-18 | 抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法 |
Country Status (12)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202434306A (zh) * | 2022-11-24 | 2024-09-01 | 瑞士商百濟神州瑞士有限責任公司 | 抗ｃｅａ抗體藥物軛合物及使用方法 |
| CN116814664B (zh) * | 2023-08-25 | 2023-12-12 | 中国医学科学院肿瘤医院 | 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3199552T (pt) * | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| ES2788979T3 (es) * | 2014-11-14 | 2020-10-23 | Hoffmann La Roche | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF |
| WO2016144976A1 (en) * | 2015-03-09 | 2016-09-15 | Kings College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| CN105753978B (zh) * | 2016-03-14 | 2020-02-07 | 中国人民解放军第二军医大学 | 一种hla-a11限制性癌胚抗原来源的表位肽及用途 |
| CA3047070A1 (en) * | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| TWI841551B (zh) * | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| BR112021026293A2 (pt) * | 2019-06-26 | 2022-03-03 | Hoffmann La Roche | Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula |
-
2022
- 2022-05-18 CN CN202280036536.1A patent/CN117396182A/zh active Pending
- 2022-05-18 JP JP2023571801A patent/JP2024522075A/ja active Pending
- 2022-05-18 AU AU2022277479A patent/AU2022277479A1/en not_active Abandoned
- 2022-05-18 WO PCT/CN2022/093565 patent/WO2022242680A1/en not_active Ceased
- 2022-05-18 EP EP22804000.2A patent/EP4340805A4/en active Pending
- 2022-05-18 IL IL308660A patent/IL308660A/en unknown
- 2022-05-18 MX MX2023013726A patent/MX2023013726A/es unknown
- 2022-05-18 KR KR1020237043895A patent/KR20240014058A/ko active Pending
- 2022-05-18 CA CA3219672A patent/CA3219672A1/en active Pending
- 2022-05-18 TW TW111118552A patent/TW202307003A/zh unknown
-
2023
- 2023-11-17 US US18/513,223 patent/US20240190989A1/en active Pending
- 2023-12-15 CO CONC2023/0017609A patent/CO2023017609A2/es unknown